RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial

Perkins, G. D., Couper, K., Connolly, B., Baillie, J. K., Bradley, J., Dark, P., De Soyza, A., Gorman, E., hamilton, L., Li, C., Lall, R., McGowan, N., Regan, S., Skilton, E., Stimpson, E., Yeung, J., & McAuley, D. (2020). RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial. Trials, [687]. https://doi.org/10.1186/s13063-020-04617-3

Published in:
Trials

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2020 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial

Gavin D. Perkins1,2, Keith Couper1,2, Bronwen Connolly3, J. Kenneth Baillie4,5, Judy M. Bradley3, Paul Dark6, Anthony De Soysa7,8, Ellen Gorman3, Alasdair Gray9,10, Louisa Hamilton1, Nicholas Han11,12, Chen Ji1, Ranjit Lall1, Nicola McGowan1, Scott Regan1, Anita K. Simonds13, Emma Skilton1, Nigel Stallard14, Emily Stimpson1, Joyce Yeung1,2 and Daniel F. McAuley3*

Abstract

Objective: The trial objective is to determine if Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) is clinically effective compared to standard oxygen therapy in patients with confirmed or suspected COVID-19.

Trial design: Adaptive (group-sequential), parallel group, pragmatic, superiority randomised controlled, open-label, multi-centre, effectiveness trial.

Participants: The trial is being conducted across approximately 60 hospitals across England, Wales, Scotland, and Northern Ireland. Inpatients at participating hospitals are eligible to participate if they have respiratory failure with suspected or proven COVID-19, and meet all of the inclusion criteria and none of the exclusion criteria.

Inclusion criteria: 1) Adults $\geq$ 18 years; 2) Admitted to hospital with suspected or proven COVID-19; 3) Receiving oxygen with fraction of inspired oxygen (FiO2) $\geq$ 0.4 and peripheral oxygen saturation (SpO2) $\leq$ 94%; and 4) Plan for escalation to tracheal intubation if needed.

Exclusion criteria: 1) Planned tracheal intubation and mechanical ventilation imminent within 1 hour; 2) Known or clinically apparent pregnancy; 3) Any absolute contraindication to CPAP or HFNO; 4) Decision not to intubate due (Continued on next page)
to ceiling of treatment or withdrawal of treatment anticipated; and 5) Equipment for both CPAP and HFNO not available.

**Intervention and comparator:** Intervention one: Continuous positive airway pressure delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion.

Intervention two: High-flow nasal oxygen delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion.

Comparator group: Standard care- oxygen delivered by face mask or nasal cannula (excluding the use of continuous positive airway pressure or high-flow nasal oxygen). Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion.

Intervention delivery continues up to the point of death, tracheal intubation, or clinical determination that there is no ongoing need (palliation or improvement).

**Main outcomes:** The primary outcome is a composite outcome comprising tracheal intubation or mortality within 30 days following randomisation. Secondary outcomes include tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay.

**Randomisation:** Participants are randomised in a 1:1:1 ratio to receive either continuous positive airway pressure, high-flow nasal oxygen or standard care. Due to the challenging environment of study delivery, a specific intervention may not always be available at the hospital site. The study uses two integrated randomisation systems to allow, where required, the site to randomise between all three interventions, between CPAP and standard care, and between HFNO and standard care. System integration ensures maintenance of balance between interventions. Randomisation is performed using a telephone-based interactive voice response system to maintain allocation concealment. The randomisation sequence was computer-generated using the minimisation method. Participant randomisation is stratified by site, gender (M/F), and age (<50, >=50 years).

**Blinding (masking):** The nature of the trial interventions precludes blinding of the researcher, patient and clinical team. Primary and secondary outcomes are all objective outcomes, thereby minimising the risk of detection bias.

**Numbers to be randomised (sample size):** 4002 participants (1334 to be randomized to each of the three study arms)

**Trial Status:** Current protocol: Version 4.0, 29th May 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021.

The trial has been awarded Urgent Public Health status by the National Institute of Health Research on 13th April 2020.

**Trial registration:** ISRCTN, ISRCTN16912075. Registered 6th April 2020, [http://www.isrctn.com/ISRCTN16912075](http://www.isrctn.com/ISRCTN16912075)

**Full protocol:** The full protocol (version 4.0, 29th May 2020) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventionsal Trials (SPIRIT) guidelines (Additional file 2).

**Keywords:** COVID-19, Randomised controlled trial, protocol, continuous positive airway pressure, oxygen inhalation therapy, high-flow nasal oxygen

---

**Supplementary information**

Supplementary information accompanies this paper at [https://doi.org/10.1186/s13063-020-04617-3](https://doi.org/10.1186/s13063-020-04617-3).

**Additional file 1.**

**Additional file 2.**

---

**Acknowledgements**

The authors would like to acknowledge the support of the Intensive Care Society, British Thoracic Society, West Midlands Academic Research Centre, members of the Data Monitoring and Ethics Committee, and members of the Trial Steering Committee.

**Authors’ contributions**

GDP and DFM conceived the study. All authors contributed to study development and writing of the protocol, and approved the final protocol.

**Funding**

The study is funded by the National Institute of Health Research. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The study sponsor and funder
have no role in the study design, data acquisition, data analysis or manuscript preparation.

Availability of data and materials
The investigator team will have full access to the final trial dataset. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Publications will be published in peer-reviewed open access journals.
Requests for data sharing will be reviewed on an individual basis by the chief investigator. The study will comply with the good practice principles for sharing individual participant data from publicly funded clinical trials and data sharing will be undertaken in accordance with the required regulatory requirements.*

Ethics approval and consent to participate
The trial received ethical approval from the London - Brighton & Sussex Research Ethics Committee on 3rd April 2020 (Reference number: 20/HRA/1696).
Consent is obtained prior to participation in individuals with mental capacity. In England, Wales and Northern Ireland, individuals that lack mental capacity may be initially enrolled without consent in accordance with the Mental Capacity Act 2005.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK. 2Critical care unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 3Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science Queen’s University Belfast, Belfast, UK. 4The Roslin Institute, University of Edinburgh, Edinburgh, UK. 5Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK. 6Division of Infection, Immunity and Respiratory Medicine, NIHR Manchester Biomedical Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 7Institute of Cellular Medicine, NIHR Biomedical Research Centre for Ageing, Newcastle University, Newcastle, UK. 8Department of Respiratory Medicine, Freeman Hospital, Newcastle, UK. 9Emergency Medicine Research Group of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK. 10Department of Emergency Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. 11Centre for Human and Applied Physiological Sciences, King’s College London, London, UK. 12Lane Fox Respiratory Service, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. 13Sleep and Ventilation Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK. 14Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.

Received: 8 July 2020 Accepted: 15 July 2020
Published online: 29 July 2020

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedicalcentral.com/submissions